search
Back to results

Treatment of Type 2 Diabetes With Linagliptin 2.5 mg Bid + Metformin 500 or 1000 mg Bid and Metformin 1000 mg Bid

Primary Purpose

Diabetes Mellitus, Type 2

Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Linagliptin + metformin
Linagliptin+metformin
Metformin
Sponsored by
Boehringer Ingelheim
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes Mellitus, Type 2

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion criteria:

  • Signed and dated written informed consent, at the latest by the date of Visit 1
  • Patients completing the entire treatment period of the double-blind study 1218.46, who are not treated with rescue medication (Visit 7)

Exclusion criteria:

  • Patients who meet one or more of the withdrawal criteria of the treatment period of the previous study 1218.46
  • Pre-menopausal women (last menstruation equal or less than 1 year prior to signing informed consent) who:
  • are nursing or pregnant,
  • or are of child-bearing potential and are not practicing an acceptable method of birth control, or do not plan to continue using this method throughout the study and do not agree to submit to periodic pregnancy testing during participation in the trial. Acceptable methods of birth control include transdermal patch, intra uterine devices/systems (IUDs/IUSs), oral, implantable or injectable contraceptives, sexual abstinence and vasectomised partner and in addition for male partners a barrier method, such as the use of condom with spermicide. No exception will be made.
  • Alcohol abuse within the 3 months prior to informed consent that would interfere with study participation
  • Drug abuse that in the opinion of the investigator would interfere with trial participation
  • Any other clinical condition which, in the opinion of the investigator, would not allow safe completion of the protocol and safe administration of the study medication

Sites / Locations

  • 1218.52.11005 Boehringer Ingelheim Investigational Site
  • 1218.52.11003 Boehringer Ingelheim Investigational Site
  • 1218.52.11002 Boehringer Ingelheim Investigational Site
  • 1218.52.11006 Boehringer Ingelheim Investigational Site
  • 1218.52.11008 Boehringer Ingelheim Investigational Site
  • 1218.52.11004 Boehringer Ingelheim Investigational Site
  • 1218.52.11007 Boehringer Ingelheim Investigational Site
  • 1218.52.11010 Boehringer Ingelheim Investigational Site
  • 1218.52.38502 Boehringer Ingelheim Investigational Site
  • 1218.52.38503 Boehringer Ingelheim Investigational Site
  • 1218.52.38504 Boehringer Ingelheim Investigational Site
  • 1218.52.38505 Boehringer Ingelheim Investigational Site
  • 1218.52.38501 Boehringer Ingelheim Investigational Site
  • 1218.52.37202 Boehringer Ingelheim Investigational Site
  • 1218.52.37201 Boehringer Ingelheim Investigational Site
  • 1218.52.37203 Boehringer Ingelheim Investigational Site
  • 1218.52.3303D Boehringer Ingelheim Investigational Site
  • 1218.52.3308B Boehringer Ingelheim Investigational Site
  • 1218.52.3305A Boehringer Ingelheim Investigational Site
  • 1218.52.3304F Boehringer Ingelheim Investigational Site
  • 1218.52.3308C Boehringer Ingelheim Investigational Site
  • 1218.52.3301A Boehringer Ingelheim Investigational Site
  • 1218.52.3305B Boehringer Ingelheim Investigational Site
  • 1218.52.3304A Boehringer Ingelheim Investigational Site
  • 1218.52.3302D Boehringer Ingelheim Investigational Site
  • 1218.52.9999 Boehringer Ingelheim Investigational Site
  • 1218.52.3307A Boehringer Ingelheim Investigational Site
  • 1218.52.3307E Boehringer Ingelheim Investigational Site
  • 1218.52.3305G Boehringer Ingelheim Investigational Site
  • 1218.52.3303A Boehringer Ingelheim Investigational Site
  • 1218.52.3308F Boehringer Ingelheim Investigational Site
  • 1218.52.3305E Boehringer Ingelheim Investigational Site
  • 1218.52.3306A Boehringer Ingelheim Investigational Site
  • 1218.52.3306C Boehringer Ingelheim Investigational Site
  • 1218.52.3302E Boehringer Ingelheim Investigational Site
  • 1218.52.3303B Boehringer Ingelheim Investigational Site
  • 1218.52.3308A Boehringer Ingelheim Investigational Site
  • 1218.52.3308D Boehringer Ingelheim Investigational Site
  • 1218.52.3308E Boehringer Ingelheim Investigational Site
  • 1218.52.3307D Boehringer Ingelheim Investigational Site
  • 1218.52.3302A Boehringer Ingelheim Investigational Site
  • 1218.52.49002 Boehringer Ingelheim Investigational Site
  • 1218.52.49006 Boehringer Ingelheim Investigational Site
  • 1218.52.49003 Boehringer Ingelheim Investigational Site
  • 1218.52.49007 Boehringer Ingelheim Investigational Site
  • 1218.52.91009 Boehringer Ingelheim Investigational Site
  • 1218.52.91001 Boehringer Ingelheim Investigational Site
  • 1218.52.91004 Boehringer Ingelheim Investigational Site
  • 1218.52.91012 Boehringer Ingelheim Investigational Site
  • 1218.52.91011 Boehringer Ingelheim Investigational Site
  • 1218.52.91003 Boehringer Ingelheim Investigational Site
  • 1218.52.91020 Boehringer Ingelheim Investigational Site
  • 1218.52.91018 Boehringer Ingelheim Investigational Site
  • 1218.52.91008 Boehringer Ingelheim Investigational Site
  • 1218.52.91002 Boehringer Ingelheim Investigational Site
  • 1218.52.91007 Boehringer Ingelheim Investigational Site
  • 1218.52.91019 Boehringer Ingelheim Investigational Site
  • 1218.52.91013 Boehringer Ingelheim Investigational Site
  • 1218.52.91015 Boehringer Ingelheim Investigational Site
  • 1218.52.91014 Boehringer Ingelheim Investigational Site
  • 1218.52.91016 Boehringer Ingelheim Investigational Site
  • 1218.52.91010 Boehringer Ingelheim Investigational Site
  • 1218.52.91006 Boehringer Ingelheim Investigational Site
  • 1218.52.37001 Boehringer Ingelheim Investigational Site
  • 1218.52.37004 Boehringer Ingelheim Investigational Site
  • 1218.52.37003 Boehringer Ingelheim Investigational Site
  • 1218.52.52006 Boehringer Ingelheim Investigational Site
  • 1218.52.52002 Boehringer Ingelheim Investigational Site
  • 1218.52.52004 Boehringer Ingelheim Investigational Site
  • 1218.52.52007 Boehringer Ingelheim Investigational Site
  • 1218.52.52008 Boehringer Ingelheim Investigational Site
  • 1218.52.52010 Boehringer Ingelheim Investigational Site
  • 1218.52.52009 Boehringer Ingelheim Investigational Site
  • 1218.52.31004 Boehringer Ingelheim Investigational Site
  • 1218.52.31005 Boehringer Ingelheim Investigational Site
  • 1218.52.31001 Boehringer Ingelheim Investigational Site
  • 1218.52.31002 Boehringer Ingelheim Investigational Site
  • 1218.52.31010 Boehringer Ingelheim Investigational Site
  • 1218.52.31013 Boehringer Ingelheim Investigational Site
  • 1218.52.31014 Boehringer Ingelheim Investigational Site
  • 1218.52.31015 Boehringer Ingelheim Investigational Site
  • 1218.52.40001 Boehringer Ingelheim Investigational Site
  • 1218.52.40005 Boehringer Ingelheim Investigational Site
  • 1218.52.40003 Boehringer Ingelheim Investigational Site
  • 1218.52.40002 Boehringer Ingelheim Investigational Site
  • 1218.52.40004 Boehringer Ingelheim Investigational Site
  • 1218.52.70001 Boehringer Ingelheim Investigational Site
  • 1218.52.70002 Boehringer Ingelheim Investigational Site
  • 1218.52.70003 Boehringer Ingelheim Investigational Site
  • 1218.52.70004 Boehringer Ingelheim Investigational Site
  • 1218.52.70006 Boehringer Ingelheim Investigational Site
  • 1218.52.70005 Boehringer Ingelheim Investigational Site
  • 1218.52.70007 Boehringer Ingelheim Investigational Site
  • 1218.52.46002 Boehringer Ingelheim Investigational Site
  • 1218.52.46003 Boehringer Ingelheim Investigational Site
  • 1218.52.46005 Boehringer Ingelheim Investigational Site
  • 1218.52.46001 Boehringer Ingelheim Investigational Site
  • 1218.52.2162A Boehringer Ingelheim Investigational Site
  • 1218.52.2162B Boehringer Ingelheim Investigational Site
  • 1218.52.9992 Boehringer Ingelheim Investigational Site
  • 1218.52.2161A Boehringer Ingelheim Investigational Site
  • 1218.52.2161B Boehringer Ingelheim Investigational Site
  • 1218.52.2163A Boehringer Ingelheim Investigational Site
  • 1218.52.2163B Boehringer Ingelheim Investigational Site
  • 1218.52.9991 Boehringer Ingelheim Investigational Site
  • 1218.52.9993 Boehringer Ingelheim Investigational Site
  • 1218.52.38003 Boehringer Ingelheim Investigational Site
  • 1218.52.38001 Boehringer Ingelheim Investigational Site
  • 1218.52.38005 Boehringer Ingelheim Investigational Site
  • 1218.52.38002 Boehringer Ingelheim Investigational Site
  • 1218.52.38004 Boehringer Ingelheim Investigational Site
  • 1218.52.38006 Boehringer Ingelheim Investigational Site

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Active Comparator

Arm Label

Linagliptin + metformin bid

Linagliptin+ metformin bid

Metformin bid

Arm Description

Linagliptin low dose + metformin 500 mg, bid

Linagliptin low dose + metformin 1000 mg bid

Metformin 1000 mg bid

Outcomes

Primary Outcome Measures

Frequency of Patients With Adverse Events (AEs)
This includes any AEs detected during routine physical examination and electrocardiogram (ECG) procedures.
Change From Baseline at Week 54 in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)
Baseline is defined as Visit 1 of 1218.52.
Change From Baseline at Week 54 in Pulse Rate
Baseline is defined as Visit 1 of 1218.52.
Frequency of Patients With Possibly Clinically Significant Abnormal Laboratory Parameters: Haematology
Possibly Clinically Significant Abnormal Laboratory Parameters: Clinical Chemistry
ULN means upper limit of normal
Clinical Relevant Drug-related Abnormal Findings in Physical Examination and ECG as Reported as AE
Frequency of patients with adverse events by treatment, primary system organ class and preferred term

Secondary Outcome Measures

Change in HbA1c From Baseline Over Time
HbA1c is measured as a percentage. Thus, this change from baseline reflects the visit HbA1c percent minus the baseline HbA1c percent. Baseline is defined as visit 1 of 1218.52.
Number of Patients With HbA1c <7.0% After 54 Weeks
Number of Patients With HbA1c <6.5% Over Time
Number of Patients With HbA1c of at Least <0.5% Over Time
Change in FPG From Baseline Over Time
Baseline is defined as visit 1 of 1218.52.
Number of Patients With Rescue Therapy
Change in HbA1c From Baseline Over Time
HbA1c is measured as a percentage. Thus, this change from baseline reflects the visit HbA1c percent minus the baseline HbA1c percent. Baseline is defined as visit 3 from study 1218.46 (NCT00915772).

Full Information

First Posted
June 2, 2009
Last Updated
April 29, 2014
Sponsor
Boehringer Ingelheim
search

1. Study Identification

Unique Protocol Identification Number
NCT00915772
Brief Title
Treatment of Type 2 Diabetes With Linagliptin 2.5 mg Bid + Metformin 500 or 1000 mg Bid and Metformin 1000 mg Bid
Official Title
Extension Study Linagliptin 2.5 mg Bid + Metformin 500 or 1000 mg Bid Versus Metformin 1000 mg Bid
Study Type
Interventional

2. Study Status

Record Verification Date
April 2014
Overall Recruitment Status
Completed
Study Start Date
June 2009 (undefined)
Primary Completion Date
June 2011 (Actual)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Boehringer Ingelheim

4. Oversight

5. Study Description

Brief Summary
A phase III randomised, double-blind parallel group extension study to investigate the efficacy and safety of twice daily administration of the free combination of linagliptin 2.5 mg + metformin 500 mg or of linagliptin 2.5 mg + metformin 1000 mg versus monotherapy with metformin 1000 mg twice daily over 54 weeks in type 2 diabetic patients previously completing the double-blind part of study 1218.46

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Single Group Assignment
Masking
Double
Allocation
Randomized
Enrollment
567 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Linagliptin + metformin bid
Arm Type
Experimental
Arm Description
Linagliptin low dose + metformin 500 mg, bid
Arm Title
Linagliptin+ metformin bid
Arm Type
Experimental
Arm Description
Linagliptin low dose + metformin 1000 mg bid
Arm Title
Metformin bid
Arm Type
Active Comparator
Arm Description
Metformin 1000 mg bid
Intervention Type
Drug
Intervention Name(s)
Linagliptin + metformin
Intervention Description
Linagliptin tablet low dose + metformin tablet 500 mg bid
Intervention Type
Drug
Intervention Name(s)
Linagliptin+metformin
Intervention Description
Linagliptin low dose tablet + metformin 1000 mg tablet bid
Intervention Type
Drug
Intervention Name(s)
Metformin
Intervention Description
Metformin 1000 mg tablet bid
Primary Outcome Measure Information:
Title
Frequency of Patients With Adverse Events (AEs)
Description
This includes any AEs detected during routine physical examination and electrocardiogram (ECG) procedures.
Time Frame
54 weeks
Title
Change From Baseline at Week 54 in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)
Description
Baseline is defined as Visit 1 of 1218.52.
Time Frame
54 weeks
Title
Change From Baseline at Week 54 in Pulse Rate
Description
Baseline is defined as Visit 1 of 1218.52.
Time Frame
54 weeks
Title
Frequency of Patients With Possibly Clinically Significant Abnormal Laboratory Parameters: Haematology
Time Frame
54 weeks
Title
Possibly Clinically Significant Abnormal Laboratory Parameters: Clinical Chemistry
Description
ULN means upper limit of normal
Time Frame
54 weeks
Title
Clinical Relevant Drug-related Abnormal Findings in Physical Examination and ECG as Reported as AE
Description
Frequency of patients with adverse events by treatment, primary system organ class and preferred term
Time Frame
Baseline and drug stop (up to 54 weeks) + 7 days
Secondary Outcome Measure Information:
Title
Change in HbA1c From Baseline Over Time
Description
HbA1c is measured as a percentage. Thus, this change from baseline reflects the visit HbA1c percent minus the baseline HbA1c percent. Baseline is defined as visit 1 of 1218.52.
Time Frame
54 weeks
Title
Number of Patients With HbA1c <7.0% After 54 Weeks
Time Frame
54 weeks
Title
Number of Patients With HbA1c <6.5% Over Time
Time Frame
54 weeks
Title
Number of Patients With HbA1c of at Least <0.5% Over Time
Time Frame
54 weeks
Title
Change in FPG From Baseline Over Time
Description
Baseline is defined as visit 1 of 1218.52.
Time Frame
54 weeks
Title
Number of Patients With Rescue Therapy
Time Frame
54 weeks
Title
Change in HbA1c From Baseline Over Time
Description
HbA1c is measured as a percentage. Thus, this change from baseline reflects the visit HbA1c percent minus the baseline HbA1c percent. Baseline is defined as visit 3 from study 1218.46 (NCT00915772).
Time Frame
78 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria: Signed and dated written informed consent, at the latest by the date of Visit 1 Patients completing the entire treatment period of the double-blind study 1218.46, who are not treated with rescue medication (Visit 7) Exclusion criteria: Patients who meet one or more of the withdrawal criteria of the treatment period of the previous study 1218.46 Pre-menopausal women (last menstruation equal or less than 1 year prior to signing informed consent) who: are nursing or pregnant, or are of child-bearing potential and are not practicing an acceptable method of birth control, or do not plan to continue using this method throughout the study and do not agree to submit to periodic pregnancy testing during participation in the trial. Acceptable methods of birth control include transdermal patch, intra uterine devices/systems (IUDs/IUSs), oral, implantable or injectable contraceptives, sexual abstinence and vasectomised partner and in addition for male partners a barrier method, such as the use of condom with spermicide. No exception will be made. Alcohol abuse within the 3 months prior to informed consent that would interfere with study participation Drug abuse that in the opinion of the investigator would interfere with trial participation Any other clinical condition which, in the opinion of the investigator, would not allow safe completion of the protocol and safe administration of the study medication
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Boehringer Ingelheim
Organizational Affiliation
Boehringer Ingelheim
Official's Role
Study Chair
Facility Information:
Facility Name
1218.52.11005 Boehringer Ingelheim Investigational Site
City
Calgary
State/Province
Alberta
Country
Canada
Facility Name
1218.52.11003 Boehringer Ingelheim Investigational Site
City
Edmonton
State/Province
Alberta
Country
Canada
Facility Name
1218.52.11002 Boehringer Ingelheim Investigational Site
City
Red Deer
State/Province
Alberta
Country
Canada
Facility Name
1218.52.11006 Boehringer Ingelheim Investigational Site
City
Vancouver
State/Province
British Columbia
Country
Canada
Facility Name
1218.52.11008 Boehringer Ingelheim Investigational Site
City
Winnipeg
State/Province
Manitoba
Country
Canada
Facility Name
1218.52.11004 Boehringer Ingelheim Investigational Site
City
Hamilton
State/Province
Ontario
Country
Canada
Facility Name
1218.52.11007 Boehringer Ingelheim Investigational Site
City
Oakville
State/Province
Ontario
Country
Canada
Facility Name
1218.52.11010 Boehringer Ingelheim Investigational Site
City
Toronto
State/Province
Ontario
Country
Canada
Facility Name
1218.52.38502 Boehringer Ingelheim Investigational Site
City
Karlovac
Country
Croatia
Facility Name
1218.52.38503 Boehringer Ingelheim Investigational Site
City
Krapinske Toplice
Country
Croatia
Facility Name
1218.52.38504 Boehringer Ingelheim Investigational Site
City
Osijek
Country
Croatia
Facility Name
1218.52.38505 Boehringer Ingelheim Investigational Site
City
Rijeka
Country
Croatia
Facility Name
1218.52.38501 Boehringer Ingelheim Investigational Site
City
Sisak
Country
Croatia
Facility Name
1218.52.37202 Boehringer Ingelheim Investigational Site
City
Pärnu
Country
Estonia
Facility Name
1218.52.37201 Boehringer Ingelheim Investigational Site
City
Tallin
Country
Estonia
Facility Name
1218.52.37203 Boehringer Ingelheim Investigational Site
City
Tallin
Country
Estonia
Facility Name
1218.52.3303D Boehringer Ingelheim Investigational Site
City
Aire sur l'Aadour
Country
France
Facility Name
1218.52.3308B Boehringer Ingelheim Investigational Site
City
Bischheim
Country
France
Facility Name
1218.52.3305A Boehringer Ingelheim Investigational Site
City
Bourges
Country
France
Facility Name
1218.52.3304F Boehringer Ingelheim Investigational Site
City
Bousse
Country
France
Facility Name
1218.52.3308C Boehringer Ingelheim Investigational Site
City
Gambsheim
Country
France
Facility Name
1218.52.3301A Boehringer Ingelheim Investigational Site
City
Grenoble cédex
Country
France
Facility Name
1218.52.3305B Boehringer Ingelheim Investigational Site
City
Guerigny
Country
France
Facility Name
1218.52.3304A Boehringer Ingelheim Investigational Site
City
Jarny
Country
France
Facility Name
1218.52.3302D Boehringer Ingelheim Investigational Site
City
La Riche
Country
France
Facility Name
1218.52.9999 Boehringer Ingelheim Investigational Site
City
La Riche
Country
France
Facility Name
1218.52.3307A Boehringer Ingelheim Investigational Site
City
La Seyne sur Mer
Country
France
Facility Name
1218.52.3307E Boehringer Ingelheim Investigational Site
City
La Seyne sur Mer
Country
France
Facility Name
1218.52.3305G Boehringer Ingelheim Investigational Site
City
Lury
Country
France
Facility Name
1218.52.3303A Boehringer Ingelheim Investigational Site
City
Mont de Marsan
Country
France
Facility Name
1218.52.3308F Boehringer Ingelheim Investigational Site
City
Mundolsheim
Country
France
Facility Name
1218.52.3305E Boehringer Ingelheim Investigational Site
City
Nevers
Country
France
Facility Name
1218.52.3306A Boehringer Ingelheim Investigational Site
City
Ortez
Country
France
Facility Name
1218.52.3306C Boehringer Ingelheim Investigational Site
City
Orthez
Country
France
Facility Name
1218.52.3302E Boehringer Ingelheim Investigational Site
City
Savonnières
Country
France
Facility Name
1218.52.3303B Boehringer Ingelheim Investigational Site
City
St Martin d'Oney
Country
France
Facility Name
1218.52.3308A Boehringer Ingelheim Investigational Site
City
Strasbourg
Country
France
Facility Name
1218.52.3308D Boehringer Ingelheim Investigational Site
City
Strasbourg
Country
France
Facility Name
1218.52.3308E Boehringer Ingelheim Investigational Site
City
Strasbourg
Country
France
Facility Name
1218.52.3307D Boehringer Ingelheim Investigational Site
City
Toulon
Country
France
Facility Name
1218.52.3302A Boehringer Ingelheim Investigational Site
City
Tours
Country
France
Facility Name
1218.52.49002 Boehringer Ingelheim Investigational Site
City
Bad Dürrheim-Sunthausen
Country
Germany
Facility Name
1218.52.49006 Boehringer Ingelheim Investigational Site
City
Köln
Country
Germany
Facility Name
1218.52.49003 Boehringer Ingelheim Investigational Site
City
München
Country
Germany
Facility Name
1218.52.49007 Boehringer Ingelheim Investigational Site
City
Schauenburg
Country
Germany
Facility Name
1218.52.91009 Boehringer Ingelheim Investigational Site
City
Aurangabad
Country
India
Facility Name
1218.52.91001 Boehringer Ingelheim Investigational Site
City
Bangalore
Country
India
Facility Name
1218.52.91004 Boehringer Ingelheim Investigational Site
City
Bangalore
Country
India
Facility Name
1218.52.91012 Boehringer Ingelheim Investigational Site
City
Bangalore
Country
India
Facility Name
1218.52.91011 Boehringer Ingelheim Investigational Site
City
Bhopal
Country
India
Facility Name
1218.52.91003 Boehringer Ingelheim Investigational Site
City
Chennai
Country
India
Facility Name
1218.52.91020 Boehringer Ingelheim Investigational Site
City
Chennai
Country
India
Facility Name
1218.52.91018 Boehringer Ingelheim Investigational Site
City
Hyderadad
Country
India
Facility Name
1218.52.91008 Boehringer Ingelheim Investigational Site
City
Jaipur
Country
India
Facility Name
1218.52.91002 Boehringer Ingelheim Investigational Site
City
Karnataka
Country
India
Facility Name
1218.52.91007 Boehringer Ingelheim Investigational Site
City
Karnataka
Country
India
Facility Name
1218.52.91019 Boehringer Ingelheim Investigational Site
City
Madurai
Country
India
Facility Name
1218.52.91013 Boehringer Ingelheim Investigational Site
City
Maharashtra
Country
India
Facility Name
1218.52.91015 Boehringer Ingelheim Investigational Site
City
Mumbai
Country
India
Facility Name
1218.52.91014 Boehringer Ingelheim Investigational Site
City
Nagpru
Country
India
Facility Name
1218.52.91016 Boehringer Ingelheim Investigational Site
City
P.O.Trivandrum
Country
India
Facility Name
1218.52.91010 Boehringer Ingelheim Investigational Site
City
Pune
Country
India
Facility Name
1218.52.91006 Boehringer Ingelheim Investigational Site
City
West Bengal
Country
India
Facility Name
1218.52.37001 Boehringer Ingelheim Investigational Site
City
Kaunas
Country
Lithuania
Facility Name
1218.52.37004 Boehringer Ingelheim Investigational Site
City
Kaunas
Country
Lithuania
Facility Name
1218.52.37003 Boehringer Ingelheim Investigational Site
City
Vilnius
Country
Lithuania
Facility Name
1218.52.52006 Boehringer Ingelheim Investigational Site
City
Aguascalientes
Country
Mexico
Facility Name
1218.52.52002 Boehringer Ingelheim Investigational Site
City
Cuernavaca
Country
Mexico
Facility Name
1218.52.52004 Boehringer Ingelheim Investigational Site
City
Guadalajara
Country
Mexico
Facility Name
1218.52.52007 Boehringer Ingelheim Investigational Site
City
Mexico
Country
Mexico
Facility Name
1218.52.52008 Boehringer Ingelheim Investigational Site
City
Mexico
Country
Mexico
Facility Name
1218.52.52010 Boehringer Ingelheim Investigational Site
City
Tijuana
Country
Mexico
Facility Name
1218.52.52009 Boehringer Ingelheim Investigational Site
City
Veracruz
Country
Mexico
Facility Name
1218.52.31004 Boehringer Ingelheim Investigational Site
City
's Hertogenbosch
Country
Netherlands
Facility Name
1218.52.31005 Boehringer Ingelheim Investigational Site
City
's Hertogenbosch
Country
Netherlands
Facility Name
1218.52.31001 Boehringer Ingelheim Investigational Site
City
Almere
Country
Netherlands
Facility Name
1218.52.31002 Boehringer Ingelheim Investigational Site
City
Beek en Donk
Country
Netherlands
Facility Name
1218.52.31010 Boehringer Ingelheim Investigational Site
City
Breda
Country
Netherlands
Facility Name
1218.52.31013 Boehringer Ingelheim Investigational Site
City
Groningen
Country
Netherlands
Facility Name
1218.52.31014 Boehringer Ingelheim Investigational Site
City
Velp
Country
Netherlands
Facility Name
1218.52.31015 Boehringer Ingelheim Investigational Site
City
Zoetermeer
Country
Netherlands
Facility Name
1218.52.40001 Boehringer Ingelheim Investigational Site
City
Alba Iulia
Country
Romania
Facility Name
1218.52.40005 Boehringer Ingelheim Investigational Site
City
Galati
Country
Romania
Facility Name
1218.52.40003 Boehringer Ingelheim Investigational Site
City
Oradea
Country
Romania
Facility Name
1218.52.40002 Boehringer Ingelheim Investigational Site
City
Ploiesti
Country
Romania
Facility Name
1218.52.40004 Boehringer Ingelheim Investigational Site
City
Satu Mare
Country
Romania
Facility Name
1218.52.70001 Boehringer Ingelheim Investigational Site
City
Moscow
Country
Russian Federation
Facility Name
1218.52.70002 Boehringer Ingelheim Investigational Site
City
Moscow
Country
Russian Federation
Facility Name
1218.52.70003 Boehringer Ingelheim Investigational Site
City
Moscow
Country
Russian Federation
Facility Name
1218.52.70004 Boehringer Ingelheim Investigational Site
City
Moscow
Country
Russian Federation
Facility Name
1218.52.70006 Boehringer Ingelheim Investigational Site
City
Moscow
Country
Russian Federation
Facility Name
1218.52.70005 Boehringer Ingelheim Investigational Site
City
St. Petersburg
Country
Russian Federation
Facility Name
1218.52.70007 Boehringer Ingelheim Investigational Site
City
St. Petersburg
Country
Russian Federation
Facility Name
1218.52.46002 Boehringer Ingelheim Investigational Site
City
Goteborg
Country
Sweden
Facility Name
1218.52.46003 Boehringer Ingelheim Investigational Site
City
Malmo
Country
Sweden
Facility Name
1218.52.46005 Boehringer Ingelheim Investigational Site
City
Stockholm
Country
Sweden
Facility Name
1218.52.46001 Boehringer Ingelheim Investigational Site
City
Uppsala
Country
Sweden
Facility Name
1218.52.2162A Boehringer Ingelheim Investigational Site
City
Bab Saâdoun Tunis
Country
Tunisia
Facility Name
1218.52.2162B Boehringer Ingelheim Investigational Site
City
Bab Sâadoun Tunis
Country
Tunisia
Facility Name
1218.52.9992 Boehringer Ingelheim Investigational Site
City
Bab Sâadoun Tunis
Country
Tunisia
Facility Name
1218.52.2161A Boehringer Ingelheim Investigational Site
City
Tunis
Country
Tunisia
Facility Name
1218.52.2161B Boehringer Ingelheim Investigational Site
City
Tunis
Country
Tunisia
Facility Name
1218.52.2163A Boehringer Ingelheim Investigational Site
City
Tunis
Country
Tunisia
Facility Name
1218.52.2163B Boehringer Ingelheim Investigational Site
City
Tunis
Country
Tunisia
Facility Name
1218.52.9991 Boehringer Ingelheim Investigational Site
City
Tunis
Country
Tunisia
Facility Name
1218.52.9993 Boehringer Ingelheim Investigational Site
City
Tunis
Country
Tunisia
Facility Name
1218.52.38003 Boehringer Ingelheim Investigational Site
City
Kiev
Country
Ukraine
Facility Name
1218.52.38001 Boehringer Ingelheim Investigational Site
City
Lviv
Country
Ukraine
Facility Name
1218.52.38005 Boehringer Ingelheim Investigational Site
City
Lvov
Country
Ukraine
Facility Name
1218.52.38002 Boehringer Ingelheim Investigational Site
City
Odessa
Country
Ukraine
Facility Name
1218.52.38004 Boehringer Ingelheim Investigational Site
City
Odessa
Country
Ukraine
Facility Name
1218.52.38006 Boehringer Ingelheim Investigational Site
City
Vinnitsa
Country
Ukraine

12. IPD Sharing Statement

Links:
URL
http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/1218/1218.52_U11-1782-01.pdf
Description
Clinical Trial Report Synopsis
URL
http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/1218/1218.52_Literature.pdf
Description
List of publications

Learn more about this trial

Treatment of Type 2 Diabetes With Linagliptin 2.5 mg Bid + Metformin 500 or 1000 mg Bid and Metformin 1000 mg Bid

We'll reach out to this number within 24 hrs